key: cord-0776997-pxof8c2o
authors: Tahmasebi, Safa; Saeed, Balsam Qubais; Temirgalieva, Elmira; Yumashev, Alexei Valerievich; El-Esawi, Mohamed A.; Navashenaq, Jamshid Gholizadeh; Valizadeh, Hamed; Sadeghi, Armin; Aslani, Saeed; Yousefi, Mehdi; Jadidi-Niaragh, Farhad; Adigozalou, Javad; Ahmadi, Majid; Roshangar, Leila
title: Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2
date: 2021-03-28
journal: Life Sci
DOI: 10.1016/j.lfs.2021.119437
sha: 657940ef74261bb75cb9c4baca27df7cedad99ec
doc_id: 776997
cord_uid: pxof8c2o

In Coronavirus disease 2019 (COVID-19), a decreased number of regulatory T (Treg) cells and their mediated factors lead to a hyperinflammatory state due to overactivation of the inflammatory cells and factors during the infection. In the current study, we evaluated the Nanocurcumin effects on the Treg cell population and corresponding factors in mild and severe COVID-19 patients. To investigate the Nanocurcumin effects, 80 COVID-19 patients (40 at the severe stage and 40 at the mild stage) were selected and classified into Nanocurcumin and placebo arms. In both the Nanocurcumin and placebo groups, the Treg cell frequency, the gene expression of Treg transcription factor forkhead box P3 (FoxP3), and cytokines (IL-10, IL-35, and TGF-β), as well as the serum levels of cytokines were measured before and after treatment. In both mild and severe COVID-19 patients, Nanocurcumin could considerably upregulate the frequency of Treg cells, the expression levels of FoxP3, IL-10, IL-35, and TGF-β, as well as the serum secretion levels of cytokines in the Nanocurcumin-treated group compared to the placebo group. The abovementioned factors were remarkably increased in the post-treatment with Nanocurcumin before pre-treatment conditions. By contrast, it has been observed no notable alterations in the placebo group. Our findings revealed the SinaCurcumin® effective function in a significant increase in the number of Treg cells and their mediated factors in the Nanocurcumin group than in the placebo group in both mild and severe patients. Hence, it would be an efficient therapeutic agent in rehabilitating COVID-19 infected patients.

Infection by SARS-CoV2 has been attributed to a broad spectrum of clinical manifestations ranging from asymptomatic course to severe conditions, including acute respiratory distress severe group had extensive alveolar damage and progressive respiratory failure that their decreased oxygen levels were more severe and they need a ventilator to help them breathe due to more severe shortness of breath and pneumonia. Organ defects and weakness were more severe in more severe patients than in mild patients, as well. Also, Severe patient group were characterized by profound lymphopenia. In severe patient group, 10% (2 out of 20) of the Nanocurcumin group and 5% (1 out of 20) of the placebo group were on ventilators that there was no significant difference between two groups of patients. The median length of hospitalization for severe patients was 10 (7-13) days. Patients with a mild clinical presentation (absence of viral pneumonia and hypoxia) may not initially require hospitalization, and most patients will be able to manage their illness at home; however, some of them need to hospitalization among 5 (4-9) days. Forty matched healthy individuals were also included in the study. To participate in the study, written informed consent was obtained from both healthy and patient groups. The ethical approval was taken from the Research Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED. REC.1398 REC. .1314 . The inclusion criteria of the patient group were confirmed etiological characteristics and clinical manifestations, approved positive RT-PCR test, and willingness of patients. The patients were excluded from the study if they had a history of allergic disorders, cancers (leukemia and lymphoma), chronic infections, and other underlying diseases. Accordingly, all patients and healthy controls that enrolled into

To investigate the treatment effects of Nanocurcumin, the intervention was applied in Nanocurcumin and placebo groups. To improve the curcumin oral bioavailability, Nanocurcumin oral capsules were administered to patients. In the Nanocurcumin-treated group, mild and severe COVID-19 patients received two doses of SinaCurcumin® (Exir Nano, Tehran, Iran) in 80 mg capsule, two times for 21 days. Moreover, in the placebo group, patients took a placebo capsule two times daily for 21 days. SinaCurcumin is a registered product from curcuminoids in Iran (IRC: 1228225765) and is prescribed as a soft gelatin capsule, consisting of 80 mg of curcuminoids, as nanomicelles. Curcuminoids, the dietary polyphenols, are extracted from the dried rhizomes of Curcuma longa L. (turmeric) and contain curcumin, bisdemethoxycurcumin (BDMC), and desmethoxycurcumin (DMC), which are termed as a C3 complex (Hatamipour et al., 2019 , Rahimi et al., 2016a . In addition to nanocurcumin and placebo, all COVID-19 patients received 40 mg Atrovastatin daily and Bromhexine every 8 hours. Additionally, Hydroxycholorquine, Corticosteroids, Protease inhibitors, Azithromycin, and Broad-spectrum antibiotics, were the most use of anti-COVID-19 regimens in patients. However, because both placebo and nanocurcumin groups took the same drugs at the same dose, the use of these drugs had no effect on the study results and the only difference between the two groups was the placebo and nanocurcumin use.

The sampling was conducted by the collection of 8 ml of blood samples from patients (pre-andpost-treatment with Nanocurcumin and placebo) using the heparinized syringes. The Peripheral blood cells (PBMCs) were isolated from whole blood of experimental cases using a densitygradient technique mediated by the 1.077 g/ml standard Ficoll (lymphosep) (Biosera, UK), J o u r n a l P r e -p r o o f centrifuged at 450g for 25 minutes, and then washed twice by phosphate buffer saline (PBS) (Sigma-Aldrich, Schnelldorf, Germany). The harvested cells (5 × 10 6 ) were cultured in a culture medium consisting of 10% heat-inactivated fetal bovine serum, 200 mM of L-glutamine, 10 ng/mL of PMA, and 100 U/ml of penicillin (eBioscience, San Diego, CA, USA). Afterward, the isolated cells were incubated in a 5% CO2 incubator at 37 °C for 48 hours. Harvested cells were utilized for cell count by flow cytometry and mRNA expression measurement by Real-time polymerase chain reaction (RT-PCR).

To analyze the frequency alteration, Flow cytometry was used to count the population of circulating Tregs among PBMCs in mild and severe COVID-19 infected patients as well as healthy subjects. Using monoclonal antibodies against the surface and intracellular markers.

Subsequently, to cell surface staining, the harvested cells (1 × 10 6 ) were washed and incubated along with monoclonal antibodies against surface and intracellular antigens, including Fluorescein isothiocyanate (FITC)-conjugated anti-human CD4, Phycoerythrin (PE)-conjugated anti-human FoxP3, and Allophycocyanin (APC)-conjugated anti-human CD25 (eBioscience) at 4 °C for 15 minutes. The FACS Calibur flow cytometer (BD Biosciences) and FlowJo software (Becton Dickinson, Mountain View, CA, USA).analyzed the population of stained cells.

The gene expression levels of Treg cell-associated transcription factor (FoxP3) and cytokines (TGF-β and IL-10) were detected in isolated PBMCs of patients and controls using Real-time polymerase chain reaction (PCR) along with SYBR green approach. For this purpose, total RNA extraction was employed from isolated cells of COVID-19 patients and healthy individuals using the RNX-PLUS Solution (SinaClon, Tehran, Iran). Subsequently, the complementary DNA J o u r n a l P r e -p r o o f (cDNA) was synthesized, applying the Revert Aid™ reverse transcriptase and random hexamer primer (Thermo Fisher Scientific). Real-time PCR measured the mRNA expression levels of the abovementioned genes based on the following steps: DNA denaturation was at 95 °C for 10 seconds, which was repeated for 40 cycles. The Annealing step was at 60 °C for 10 seconds, which was followed by the extension step at 72°C for 20 seconds. The electrophoresis analysis was performed to prove the gene amplification and DNA sequencing, utilizing agarose gel (2%) and Biosystems (Seqlab, Gottingen, Germany). Of note, the curves were a plot employing the six standards, prepared from 10-fold serial dilutions obtained from genes concentrated samples. Data were analyzed using the 2 −ΔΔCT formula, the comparative Ct method. Also, the relative expression of target genes was compared with the housekeeping gene. Here, the β-actin was a housekeeping gene. The primer sequences have been detailed in Table 2 .

Protein secretion levels of Treg-associated cytokines (TGF-β, IL-10, and IL-35) were measured in the serum samples of mild and COVID-19 patients in pre-and-post-treatment conditions as well as healthy subjects, employing the ELISA kit (MyBioSource, Nivelles, Belgium). ELISA technique assessed the serum levels of cytokines according to the following steps: 1) 100 μL of coating antibody was added to the wells to coat the 96-well assay plates. 2) The plates were incubated at 4°C overnight and then washed by PBS consisting of Tween-20 (0.05%). 3) To eliminate the uncoated antibodies, a blocking buffer containing 2% milk in PBS was poured into wells. 4) The plates were incubated on a shaker at room temperature for 2 hours and then washed by PBS. 5) The plates were incubated with 100 μL of standards and samples for 1 hour. 6) 100 μL of a biotinylated antibody was added to wells and incubated for 1 hour. 7) 100 μL of the avidin-biotin-peroxidase complex was poured into wells, and followed by incubation for 30 J o u r n a l P r e -p r o o f minutes. 8) In the last step, the plates were incubated with 100 μL of tetramethylbenzidine (TMB) substrate for 30 minutes, and then the reaction was stopped. The Medgenix ELISA reader (BP-800; Biohit, Helsinki, Finland) read the absorbance values of samples and standards at 450 nm.

In the current study, SPSS PC Statistics Software (version 19.0; SPSS Inc, Chicago, IL) was applied to perform the statistical analysis. The unpaired Student's t-test was employed to analyze the statistical differences of immunologic parameters between the control group and the COVID-19 patient group. The one-way ANOVA was utilized to compare the statistical differences of immunologic parameters in patient groups between before-and-after treatment. Also, the Shapiro-Wilk test controlled the proportion of data to normal ranges. Descriptive data were indicated as the mean ± SD and P < 0.05 was represented as statistically significant. The GraphPad Prism was applied to draw the graphs (version 7.00 for Windows; GraphPad Software, La Jolla, CA; www.graphpad.com).

The comparison of Treg cell percentage between baseline and disease condition revealed a P=0.066), and TGF-β (P=0.0036, P=0.0001, and P=0.038) in the mild patient group versus controls, severe patient group versus controls, and severe patients group versus mild patient group for each factor, respectively ( Figure 1B and Table 3 ). The cytokine secretion levels of Treg cells were also evaluated in serum samples of both COVID-19 patients and control groups using ELISA. According to findings, the concentration of IL-10 (P=0.016 and P=0.0012), IL-35 (P=0.01 and P<0.0001), and TGF-β (P=0.0003 and P=0.0001) were found to be significantly lower in mild patients versus controls and in severe patients versus controls, respectively.

Besides, it was found that the secretion level of IL-35 was considerably decreased in severe patients than in mild cases (P=0.0045) ( Figure 1C and Table 4 ).

In the mild stage of COVID-19 patients, Nanocurcumin could notably build up the number of Treg cells from 3.295% ± 1.262% pre-treatment to 4.308% ± 1.737% post-treatment with the drug (P=0.0049); while, no notable variation was gained in the placebo group after and before treatment (4.074% ± 1.595% vs. 4.025% ± 1.424%, P=0.9). Moreover, in severe stage COVID-19 patients, the Nanocurcumin treated group indicated a considerable elevation in the frequency of Treg cell after treatment (3.807% ± 1.669%) compared to before treatment (2.525% ± 1.219%) with Nanocurcumin (P=0.0085). By contrast, in the placebo group, the number of Treg cells did not significantly change after and before treatment (3.053% ± 1.468% vs. 3.269% ± 1.307%, P=0.461) ( Figure 2 ).

It was found that in mild patients receiving Nanocurcumin, the expression levels of FoxP3 (P=0.0062), IL-10 (P=0.0051), IL-35 (P=0.0044), and TGF-β (P=0.032) were significantly J o u r n a l P r e -p r o o f upregulated after treatment. Also, we found significantly upregulated gene expression in IL-10 (P=0.018) and IL-35 (P=0.0083) when compared Nanocurcumin received patients with placebo received group ( Figure 3A ). Similarly, a considerably higher expression level of FoxP3 (P=0.042) and IL-10 (P=0.045) were detected in Nanocurcumin received patients after treatment in severe COVID-19 patients ( Figure 3B ). compared with pre-treatment condition in the Nanocurcumin receiving group. In contrast, no remarkable alteration in serum secretion levels of IL-10, IL-35, and TGF-β were found in the placebo group after treatment vs. before treatment. Besides, serum secretion level of IL-10 was found to be considerably higher in the Nanocurcumin patient group in comparison with the placebo group after receiving treatment (46.04 ± 20.86 vs. 29.43 ± 16.61, P=0.0094); however, no meaningful differences were observed in secretion levels of TGF-β and IL-35 in the Nanocurcumin and placebo groups, after treatment ( Figure 4A and 55.87 ± 24.62, P=0.0036) cytokines in post-treatment Nanocurcumin group when compared with pre-treatment condition. Moreover, a remarkably increased level of IL-10 concentration was detected in the Nanocurcumin-treated group in comparison with the placebo group after J o u r n a l P r e -p r o o f treatment (38.24 ± 18.17 vs. 19.21 ± 9.40, P=0.0009). On the other hand, it was found that the serum secretion levels of IL-10, IL-35, and TGF-β were not considerably higher in the placebo group post-treatment vs pre-treatment. Moreover, no considerable alterations were found in serum secretion levels of mentioned cytokines between Nanocurcumin and placebo groups ( Figure 4B and Table 5 ).

Clinical symptoms, including fever, cough, dyspnea, and headache were also assessed in COVID-19 patients before and after treatment with nanocurcumin. Moreover, some laboratory findings, including White blood cell (WBC) count, lymphocyte count, platelet count, creatinine, Lactate dehydrogenase, and bilateral involvement of chest radiographs were examined in patients before and after treatment with nanocurcumin. Treatment with nanocurcumin was associated with statistically significant improvement of clinical symptoms in the mild and severe patient group after treatment compared to before treatment (P<0.0001) ( Table 6 and 7). However, there was no significant difference in most clinical symptoms and laboratory findings in the placebotreated group before and after treatment. In mild stage patients, the mortality rate was found to be 0% (0 out of 20) in the nanocurcumin-treated group and 5% (1 out of 20) in the placebo-treated group. Besides, in severe patients, the Nanocurcumin group had 5% mortality rate (1 out of 20) and the placebo group had 25% mortality rate (5 out of 20). According to findings, the mortality rate was demonstrated considerably higher in the placebo-treated group than in the nanocurcumin-treated group in patients (mild and severe) (P < 0.0001).

The importance of immune system responses in the COVID-19 immunopathogenesis and the lack of approved and practical treatment prompted us to investigate the therapeutic effects of a J o u r n a l P r e -p r o o f potent novel Nanocurcumin-based formulation called SinaCurcumin® in COVID-19 patients.

Curcumin is a bioactive-ingredient traditional medicine that originated from the rhizomes of Curcuma longa L (Heger et al. , 2014) . At the molecular level, curcumin can modulate various signaling molecules and functions on multiple targets in different cellular pathways (Imran et al. , 2018, Willenbacher and Khan, 2019) . Curcumin is mostly known as a modulatory agent, which can modulate the inflammatory responses and inhibit infections. Interestingly, curcumin obtained much success in infections, cancers, autoimmunities, inflammatory diseases, etc. as a therapeutic or protective natural agent (Flora et al. , 2013 , Imran et al., 2018 , Rahimi and Kazemi Oskuee, 2014 . According to some references curcumin has major problems such as poor bioavailability because of its poor solubility in water, a higher rate of metabolic activity and rapid excretion from the body; where as these restrictions have been solved in Nano range formulation of curcumin, namely nanocurcumin (Gera et al. , 2017, Hanna and Saad, 2020) . The nanoformulation of curcumin termed nanocurcumin paved the way for some relevant restrictions to curcumin, such as bioavailability. This formulation increases dissolution rate, saturation solubility, bioavailability, and drug stability. Nanomicelles containing curcumin is a registered curcumin product (SinaCurcumin®) for oral use. Each soft gel of SinaCurcumin® contains 80 mg of curcumin as a nano micelle. The percentage of encapsulation of curcumin in this nano micelle is near to 100% and their sizes are around 10 nm. SinaCurcumin® has a significantly higher bioavailability after oral use compared to a simple powder form of curcumin with the following mechanisms. After oral administration, the soft gels of SinaCurcumin® open and pass through the small intestine in less than 15 minutes in the stomach. These nano micelles after reaching the small intestinecould bedissolved in unstirred water layer (Hatamipour et al., 2019 , Rahimi et al. , 2016b .

Relying on the benefits of the SinaCurcumin®, including anti-inflammatory and anti-microbial functions, we were prompted to evaluate the efficacy of SinaCurcumin® on Treg cell responses in mild and severe COVID-19 infected patients.

Based on obtained findings, Nanocurcumin could significantly increase the number of Treg cells in both mild and severe infected patients in comparison with those received placeboes.

Moreover, the expression levels of all FoxP3, TGF-β, IL-10, and IL-35 factors were notably upregulated in Nanocurcumin treated groups of both mild and severe patients after treatment versus before treatment; while, no considerable alterations were found in the placebo group. We found that the serum levels of all IL-10, IL-35, and TGF-β cytokines were remarkably enhanced after treatment by Nanocurcumin in comparison with pre-treatment conditions. However, the placebo group showed no meaningful differences after receiving treatment in comparison to before treatment. Additionally, in both mild and severe-infected patients, a higher secretion level of IL-10 was observed in the Nanocurcumin-received group than in the placebo group, after treatment. Our findings also revealed an overall improvement in clinical symptoms of patients treated with Nanocurcumin. According to the results, Nanocurcumin could significantly mitigate the fatality in the mild and severe-treated patients, which proposes the potent therapeutic function of Nanocurcumin against SARS-CoV2 infection. Given the role of the immune system in defense against SARS-CoV2 as well as the viral immunopathogenesis, targeting immune responses such as suppressing Th1 and Th17 cell responses and augmenting the Treg cell responses can be effective in reducing the inflammation and accelerating the rehabilitation and recovery process in infected patients (Tahmasebi et al. , 2020a) . The reduced frequency and dysfunction of Treg cells in the course of SARS-CoV2 infection lead to disease progression, respiratory system injury, and ARDS (Qin et al. , 2020b , Sadeghi et al. , 2020 . Also, the (Ahmadi et al. , 2020a . Also, it was found that curcumin acted as a doubleedged sword in attenuating the lung injury in acute lung injury mice, on the one hand, it downregulated the proinflammatory cytokines and on the other hand, it increased the differentiation of Treg cells and the expression of IL-10 cytokine, as an anti-inflammatory cytokine (Chai et al. , 2020) . Another study examined the therapeutic effect of curcumin against COVID-19 and provided promising results regarding the high affinity of curcumin to bind to viral nucleocapsid, membrane, and spike proteins, and the efficient role of curcumin as a potential natural therapeutic agent in the development of anti-SARS-CoV2 drugs (Suravajhala et al. , 2020b) . In a study by Tahmasebi (Das et al. , 2020 , Mathew and Hsu, 2018 , Moghadamtousi et al. , 2014 . In addition to the mentioned studies, some other related studies suggest the usage of Nanocurcumin as a potent therapeutic agent against SARS-CoV2 due to the anti-viral and anti-J o u r n a l P r e -p r o o f inflammatory activities (Liu and Ying, 2020 , Manoharan et al. , 2020 , Suravajhala et al. , 2020a .

In conclusion, regarding the importance of Treg cells in suppressing inflammation and inducing the immune system homeostasis, a decreased number of Tregs could be considered as one of the important causes of the hyperactivated immune system, hyper inflammation, and lung injury in the COVID-19 patients, mostly in severe condition. Therefore, Nanocurcumin would be effective in reducing inflammation and improving 2019-nCoV patients by upregulating the activity of Treg cells. Also, the reduction in mortality in treated patients was one of the promising results of Nanocurcumin treatment in COVID-19. We proposed that Nanocurcumin may represent a potential treatment option against SARS-CoV2; however, further research is necessary to evaluate the anti-inflammatory and immunomodulatory potential uses of this compound in COVID-19 patients. Nanocurcumin could significantly increase the frequency of Treg cells in the Nanocurcumintreated group in mild COVID-19 patients after treatment vs before treatment (P=0.0049). C. In severe patients, considerable enhance was found in the number of Tregs in Nanocurcumintreated patients after treatment vs before treatment (P=0.0085). No significant differences were observed in the placebo group in both mild and severe patients after and before treatment (P=0.9 and P=0.461, respectively). Mild patient group, n=40; severe patient group, n=40; Nanocurcumin treated group, n=20; placebo-treated group, n=20. Results are given as, mean ± SD. P<0.05 describes statistically significant. COVID-19, Coronavirus disease 2019; Treg, Tregulatory cell. TGF-β were found in the placebo group after treatment vs. before treatment. Also, the serum secretion level of IL-10 was considerably higher in the Nanocurcumin-treated group than in the placebo group after treatment (P=0.0094), but no significant differences were observed in secretion levels of IL-35 and TGF-β among Nanocurcumin and placebo groups, after treatment.

In severe patients, the secretion levels of IL-10 (P=0.0018), IL-35 (P=0.0013), and TGF-β (P=0.0036) cytokines were meaningfully higher in post-treatment with Nanocurcumin in the treated group when compared with pre-treatment condition. Besides, the serum secretion level of IL-10 was found to be considerably increased in the Nanocurcumin patient group in comparison with the placebo patient group after treatment (P=0.0009). No significant alterations in the serum secretion level of cytokines were observed in the placebo-treated group after treatment vs before treatment. Mild patient group, n=40; severe patient group, n=40; Nanocurcumin treated group, n=20; placebo-treated group, n=20. Results are given as, mean ± SD. (+) in graphs indicates the mean. P<0.05 describes statistically significant. COVID-19, Coronavirus disease 2019; Treg, Tregulatory cell; IL, interleukin; TGF-β, Transforming growth factor-beta. ns Cough (%) 7 (35%) 1 (5%) <0.0001 11 (55%) 3 (20%) 0.004 Dyspnea (%) 6 (30%) 2 (1%) <0.0001 4 (20%) 1 (5.2%) 0.01

13 (65%) 4 (20%) <0.0001 9 (45%) 7 (36%) ns 

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment. Systems biology in reproductive medicine

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial

The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial

Disturbed Th17/Treg balance, cytokines, and miRNAs in peripheral blood of patients with Behcet's disease

Curcumin regulates the differentiation of naïve CD4+ T cells and activates IL-10 immune modulation against acute lung injury in mice

Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation. 2020;130. da Silva Antonio A, Wiedemann LSM, Veiga-Junior VF. Natural products' role against COVID-19

An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study

Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis

Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis

The imbalance of Th17/Treg axis involved in the pathogenesis of preeclampsia

Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma

Nanocurcumin: a promising therapeutic advancement over native curcumin. Critical reviews in therapeutic drug carrier systems

Nanoformulations of curcumin: an emerging paradigm for improved remedial application

Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

Therapeutic roles of curcumin: lessons learned from clinical trials

Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function

Nanocurcumin: preparation, characterization and cytotoxic effects towards human laryngeal cancer cells

Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iranian journal of basic medical sciences

The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer

Cucurmin, anticancer, & antitumor perspectives: A comprehensive review. Critical reviews in food science and nutrition

Changes in Th17 cells frequency and function after ozone therapy used to treat multiple sclerosis patients

Curcumin use in pulmonary diseases: State of the art and future perspectives

The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia

Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management

Antiviral potential of curcumin

A review on antibacterial, antiviral, and antifungal activity of curcumin

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Curcumin from traditional Iranian medicine to molecular medicine

The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial

Novel delivery system for natural products: Nano-curcumin formulations

Cytokine storm in COVID-19: Potential therapeutics for immunomodulation

Pharmacoimmunomodulatory therapy in COVID-19

Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls

Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients

Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

The outlook for diagnostic purposes of the 2019-novel coronavirus disease

Immunopathological characteristics of coronavirus disease

The laboratory tests and host immunity of COVID-19 patients with different severity of illness

High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients

Curcumin: New Insights into an Ancient Ingredient against Cancer

COVID-19: immunopathogenesis and Immunotherapeutics

The authors gratefully acknowledge the financial support of this project by the Stem Cell Research Center (SCRC) at Tabriz University of Medical Sciences (grant No. 65660).